ramucirumab - Articles and news items

Ramucirumab improves progression-free survival in bladder cancer trial

Industry news / 28 September 2015 / Victoria White

Median progression-free survival was 5.4 months on the ramucirumab-docetaxel arm as compared to 2.8 months for patients treated with docetaxel alone…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+